New Direction Article

Resverlogix’s Dr. Ewelina Kulikowski, Senior Vice President, R&D, has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.” The article focuses on how BET inhibition has an impact on multiple biologies with the potential to treat a variety of conditions such as cancer, inflammatory, neurodegenerative, metabolic and cardiovascular disorders.

You can read “New Direction,” by Dr. Kulikowski HERE.